Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Irene Ghobrial, M.D.

TitleAssociate Professor of Medicine
InstitutionDana-Farber Cancer Institute
DepartmentMedicine
AddressDana Farber Cancer Institute
Mayer 1B-127
44 Binney St
Boston MA 02115
Phone617/632-4166
Fax617/632-4862

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Leblebjian H, Agarwal A, Ghobrial I. Novel treatment options for waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S310-6.
    View in: PubMed
  2. Bianchi G, Sacco A, Kumar S, Rossi G, Ghobrial I, Roccaro A. Candidate genes of Waldenström's macroglobulinemia: current evidence and research. Appl Clin Genet. 2013; 6:33-42.
    View in: PubMed
  3. Liu Y, Quang P, Braggio E, Ngo H, Badalian-Very G, Flores L, Zhang Y, Sacco A, Maiso P, Azab AK, Azab F, Carrasco R, Rollins BJ, Roccaro AM, Ghobrial IM. Novel Tumor Suppressor Function of Glucocorticoid-Induced TNF Receptor GITR in Multiple Myeloma. PLoS One. 2013; 8(6):e66982.
    View in: PubMed
  4. Ghobrial IM. Revisiting treatment paradigms in high-risk smoldering multiple myeloma: out with the old, in with the new? Leuk Lymphoma. 2013 Oct; 54(10):2328-30.
    View in: PubMed
  5. Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi AA, Senapedis W, Saint-Martin JR, Kashyap T, Shacham S, Kauffman M, Gu Y, Wu L, Ghobrial I, Zhan F, Kung AL, Schey SA, Richardson P, Munshi NC, Anderson KC. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014 Jan; 28(1):155-65.
    View in: PubMed
  6. Ghobrial IM. Update on Waldenström's Macroglobulinemia. Clin Adv Hematol Oncol. 2013 Apr; 11(4):244-6.
    View in: PubMed
  7. Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, Anderson KC, Scadden DT, Ghobrial IM. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013 Apr 1; 123(4):1542-55.
    View in: PubMed
  8. Agarwal A, Ghobrial IM. The bone marrow microenvironment in waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):218-21.
    View in: PubMed
  9. Sacco A, Zhang Y, Maiso P, Manier S, Rossi G, Treon SP, Ghobrial IM, Roccaro AM. microRNA Aberrations in Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):205-7.
    View in: PubMed
  10. Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F, Chuma S, Kunsman J, Donovan A, Masood F, Warren D, Rodig S, Anderson KC, Richardson PG, Weller E, Matous J. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood. 2013 Feb 21; 121(8):1296-303.
    View in: PubMed
  11. Weinstock M, Ghobrial IM. Extramedullary multiple myeloma. Leuk Lymphoma. 2013 Jun; 54(6):1135-41.
    View in: PubMed
  12. Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013 Mar 14; 121(11):1961-7.
    View in: PubMed
  13. Rosovsky R, Hong F, Tocco D, Connell B, Mitsiades C, Schlossman R, Ghobrial I, Lockridge L, Warren D, Bradwin G, Doyle M, Munshi N, Soiffer RJ, Anderson KC, Weller E, Richardson P. Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013 Feb; 160(3):351-8.
    View in: PubMed
  14. Ghobrial IM. Choice of therapy for patients with waldenstrom macroglobulinemia. J Clin Oncol. 2013 Jan 20; 31(3):291-3.
    View in: PubMed
  15. Azab AK, Weisberg E, Sahin I, Liu F, Awwad R, Azab F, Liu Q, Griffin JD, Ghobrial IM. The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression. Leukemia. 2013 Apr; 27(4):961-4.
    View in: PubMed
  16. Agarwal A, Ghobrial IM. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res. 2013 Mar 1; 19(5):985-94.
    View in: PubMed
  17. Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, Garcia-Sanz R, Ocio EM, Morra E, Morel P, Anderson KC, Patterson CJ, Munshi NC, Tedeschi A, Joshua DE, Kastritis E, Terpos E, Ghobrial IM, Leleu X, Gertz MA, Ansell SM, Morice WG, Kimby E, Treon SP. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013 Jan; 160(2):171-6.
    View in: PubMed
  18. Roccaro AM, Sacco A, Jia X, Banwait R, Maiso P, Azab F, Flores L, Manier S, Azab AK, Ghobrial IM. Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia. Clin Cancer Res. 2012 Dec 15; 18(24):6609-22.
    View in: PubMed
  19. Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol. 2012; 2012:157496.
    View in: PubMed
  20. Reagan MR, Seib FP, McMillin DW, Sage EK, Mitsiades CS, Janes SM, Ghobrial IM, Kaplan DL. Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ. J Breast Cancer. 2012 Sep; 15(3):273-82.
    View in: PubMed
  21. Bianchi G, Ghobrial IM. Molecular mechanisms of effectiveness of novel therapies in multiple myeloma. Leuk Lymphoma. 2013 Feb; 54(2):229-41.
    View in: PubMed
  22. Ghobrial IM, Moreau P, Harris B, Poon T, Jourdan E, Maisonneuve H, Benhadji KA, Hossain AM, Nguyen TS, Wooldridge JE, Leblond V. A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia. Clin Cancer Res. 2012 Sep 15; 18(18):5043-50.
    View in: PubMed
  23. Zhang Y, Roccaro AM, Rombaoa C, Flores L, Obad S, Fernandes SM, Sacco A, Liu Y, Ngo H, Quang P, Azab AK, Azab F, Maiso P, Reagan M, Brown JR, Thai TH, Kauppinen S, Ghobrial IM. LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood. 2012 Aug 23; 120(8):1678-86.
    View in: PubMed
  24. Maiso P, Ghobrial IM. Would the real myeloma cell please stand up? Leuk Lymphoma. 2012 Oct; 53(10):1851-2.
    View in: PubMed
  25. Howard S, Jagannathan J, Krajewski K, Giardino A, Zukotynski K, O'Regan K, Ghobrial I, Ramaiya N. Multimodality imaging in amyloidosis. Cancer Imaging. 2012; 12:109-17.
    View in: PubMed
  26. Ghobrial IM. Myeloma as a model for the process of metastasis: implications for therapy. Blood. 2012 Jul 5; 120(1):20-30.
    View in: PubMed
  27. Bianchi G, Ghobrial IM. Does my patient with a serum monoclonal spike have multiple myeloma? Hematol Oncol Clin North Am. 2012 Apr; 26(2):383-93, ix.
    View in: PubMed
  28. Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Redman KC, McKenney M, Warren D, Noonan K, Lunde L, Doss D, Colson K, Hideshima T, Mitsiades C, Munshi NC, Anderson KC. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol. 2012 May; 88(5):446-9.
    View in: PubMed
  29. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart CP, Roccaro AM, Sacco A, Ngo HT, Lin CP, Kung AL, Carrasco RD, Vanderkerken K, Ghobrial IM. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood. 2012 Jun 14; 119(24):5782-94.
    View in: PubMed
  30. Gaballa MR, Laubach JP, Schlossman RL, Redman K, Noonan K, Mitsiades CS, Ghobrial IM, Munshi N, Anderson KC, Richardson PG. Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8.
    View in: PubMed
  31. Ghobrial IM. Are you sure this is Waldenstrom macroglobulinemia? Hematology Am Soc Hematol Educ Program. 2012; 2012:586-94.
    View in: PubMed
  32. Weisberg E, Azab AK, Manley PW, Kung AL, Christie AL, Bronson R, Ghobrial IM, Griffin JD. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia. 2012 May; 26(5):985-90.
    View in: PubMed
  33. Issa NC, Koo S, Lynch RC, Gay C, Hammond SP, Baden LR, Ghobrial IM, Finkelman MA, Marty FM. Serum galactomannan and (1->3)-ß-D-glucan assays for patients with multiple myeloma and Waldenstrom's macroglobulinemia. J Clin Microbiol. 2012 Mar; 50(3):1054-6.
    View in: PubMed
  34. Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Mitsiades CS, Rosenblatt J, Mahindra A, Raje N, Munshi N, Anderson KC. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):1-7.
    View in: PubMed
  35. Azab AK, Quang P, Azab F, Pitsillides C, Thompson B, Chonghaile T, Patton JT, Maiso P, Monrose V, Sacco A, Ngo HT, Flores LM, Lin CP, Magnani JL, Kung AL, Letai A, Carrasco R, Roccaro AM, Ghobrial IM. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 2012 Feb 9; 119(6):1468-78.
    View in: PubMed
  36. Reagan MR, Ghobrial IM. Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res. 2012 Jan 15; 18(2):342-9.
    View in: PubMed
  37. Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB, Zhang Y, Liu Y, Sacco A, Ngo H, Azab F, Quang P, Rodig SJ, Lin CP, Roccaro AM, Rommel C, Ghobrial IM. Defining the role of TORC1/2 in multiple myeloma. Blood. 2011 Dec 22; 118(26):6860-70.
    View in: PubMed
  38. Sacco A, Ghobrial IM, Roccaro AM. Anti-Angiogenic Therapies in the Treatment of Waldenstrom's Macroglobulinemia. Curr Cancer Drug Targets. 2011 Nov 1; 11(9):1025-9.
    View in: PubMed
  39. Azab F, Azab AK, Maiso P, Calimeri T, Flores L, Liu Y, Quang P, Roccaro AM, Sacco A, Ngo HT, Zhang Y, Morgan BL, Carrasco RD, Ghobrial IM. Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia. Clin Cancer Res. 2012 Jan 1; 18(1):91-104.
    View in: PubMed
  40. Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M, Martin T, Schlossman R, Ghobrial IM, Munshi N, Laubach J, Allerton J, Hideshima T, Colson K, Poradosu E, Gardner L, Sportelli P, Anderson KC. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011 Nov 10; 29(32):4243-9.
    View in: PubMed
  41. Laubach JP, Mitsiades CS, Mahindra A, Luskin MR, Rosenblatt J, Ghobrial IM, Schlossman RL, Avigan D, Raje N, Munshi NC, Anderson KC, Richardson PG. Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16.
    View in: PubMed
  42. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep 16; 146(6):904-17.
    View in: PubMed
  43. Ghobrial IM, Maiso P, Azab A, Liu Y, Zhang Y, Issa G, Azab F, Sacco A, Quang P, Ngo H, Roccaro A. The bone marrow microenvironment in waldenstrom macroglobulinemia. Ther Adv Hematol. 2011 Aug; 2(4):267-72.
    View in: PubMed
  44. Issa GC, Leblebjian H, Roccaro AM, Ghobrial IM. New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia. Curr Opin Hematol. 2011 Jul; 18(4):260-5.
    View in: PubMed
  45. Banwait R, O'Regan K, Campigotto F, Harris B, Yarar D, Bagshaw M, Leleu X, Leduc R, Ramaiya N, Weller E, Ghobrial IM. The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. Am J Hematol. 2011 Jul; 86(7):567-72.
    View in: PubMed
  46. Richardson PG, Laubach J, Mitsiades CS, Schlossman RL, Ghobrial IM, Munshi NC, Anderson KC. MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. Oncology (Williston Park). 2011 Jun; 25(7):594, 596.
    View in: PubMed
  47. Ghobrial IM, Munshi NC, Harris BN, Shi P, Porter NM, Schlossman RL, Laubach JP, Anderson KC, Desaiah D, Myrand SP, Wooldridge JE, Richardson PG, Abonour R. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol. 2011 Jul; 86(7):573-8.
    View in: PubMed
  48. Ghobrial IM, Zhang Y, Liu Y, Ngo H, Azab F, Sacco A, Azab A, Maiso P, Morgan B, Quang P, Issa GC, Leleu X, Roccaro AM. Targeting the bone marrow in Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S65-9.
    View in: PubMed
  49. Azab AK, Azab F, Quang P, Maiso P, Sacco A, Ngo HT, Liu Y, Zhang Y, Morgan BL, Roccaro AM, Ghobrial IM. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. Clin Cancer Res. 2011 Jul 1; 17(13):4389-99.
    View in: PubMed
  50. Neri P, Ren L, Azab AK, Brentnall M, Gratton K, Klimowicz AC, Lin C, Duggan P, Tassone P, Mansoor A, Stewart DA, Boise LH, Ghobrial IM, Bahlis NJ. Integrin ß7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood. 2011 Jun 9; 117(23):6202-13.
    View in: PubMed
  51. Leleu X, Xie W, Bagshaw M, Banwait R, Leduc R, Roper N, Weller E, Ghobrial IM. The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia. Clin Cancer Res. 2011 May 1; 17(9):3013-8.
    View in: PubMed
  52. C Potts B, X Albitar M, C Anderson K, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, C Cusack J, Fenical W, M Ghobrial I, Groll M, R Jensen P, S Lam K, K Lloyd G, McBride W, J McConkey D, P Miller C, T C Neuteboom S, Oki Y, Ovaa H, Pajonk F, G Richardson P, M Roccaro A, M Sloss C, A Spear M, Valashi E, Younes A, Palladino MA. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar; 11(3):254-84.
    View in: PubMed
  53. Sacco A, Aujay M, Morgan B, Azab AK, Maiso P, Liu Y, Zhang Y, Azab F, Ngo HT, Issa GC, Quang P, Roccaro AM, Ghobrial IM. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. Clin Cancer Res. 2011 Apr 1; 17(7):1753-64.
    View in: PubMed
  54. Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, Schlossman R, Leduc R, Chuma S, Kunsman J, Laubach J, Jakubowiak AJ, Maiso P, Roccaro A, Armand P, Dollard A, Warren D, Harris B, Poon T, Sam A, Rodig S, Anderson KC, Richardson PG. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011 Mar; 12(3):263-72.
    View in: PubMed
  55. Ghobrial IM, Zhang Y, Liu Y, Ngo H, Azab F, Sacco A, Azab A, Maiso P, Morgan B, Quang P, Issa G, Roccaro A. The bone marrow niche in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):118-20.
    View in: PubMed
  56. Leleu X, Koulieris E, Maltezas D, Itzykson R, Xie W, Manier S, Dulery R, Boyle E, Gauthier J, Poulain S, Tatiana T, Panayiotidis P, Bradwell AR, Harding S, Leblond V, Kyrtsonis MC, Ghobrial IM. Novel M-component based biomarkers in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):164-7.
    View in: PubMed
  57. Sacco A, Maiso P, Azab A, Azab F, Zhang Y, Liu Y, Ngo HT, Morgan B, Quang P, Issa G, Ghobrial IM, Roccaro AM. Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):109-11.
    View in: PubMed
  58. Runnels JM, Carlson AL, Pitsillides C, Thompson B, Wu J, Spencer JA, Kohler JM, Azab A, Moreau AS, Rodig SJ, Kung AL, Anderson KC, Ghobrial IM, Lin CP. Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. J Biomed Opt. 2011 Jan-Feb; 16(1):011006.
    View in: PubMed
  59. Calvo KR, Landgren O, Roccaro AM, Ghobrial IM. Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma. Semin Hematol. 2011 Jan; 48(1):39-45.
    View in: PubMed
  60. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, Porrata LF, Ansell SM, Colgan JP, Jacobsen ED, Ghobrial IM, Habermann TM. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011 Feb; 25(2):341-7.
    View in: PubMed
  61. Roper N, DeAngelo DJ, Kuo F, Dal Cin P, Ghobrial I, Aster JC. An asymptomatic 61-year-old man with BCR-ABL-positive bone marrow following autologous transplantation for multiple myeloma. Am J Hematol. 2010 Dec; 85(12):944-6.
    View in: PubMed
  62. Sacco A, Roccaro A, Ghobrial IM. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. Oncotarget. 2010 Nov; 1(7):578-82.
    View in: PubMed
  63. Sacco A, Issa GC, Zhang Y, Liu Y, Maiso P, Ghobrial IM, Roccaro AM. Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology. J Hematol Oncol. 2010; 3:38.
    View in: PubMed
  64. Sacco A, Ghobrial IM, Roccaro AM. Epigenetics in Waldenström's macroglobulinemia. Epigenomics. 2010 Oct; 2(5):691-6.
    View in: PubMed
  65. Rourke M, Anderson KC, Ghobrial IM. Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma. 2010 Oct; 51(10):1779-92.
    View in: PubMed
  66. Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Poon T, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol. 2010 Sep; 85(9):670-4.
    View in: PubMed
  67. Richardson P, Mitsiades C, Laubach J, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson K. Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010; 4:215-45.
    View in: PubMed
  68. Roccaro AM, Sacco A, Jia X, Azab AK, Maiso P, Ngo HT, Azab F, Runnels J, Quang P, Ghobrial IM. microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood. 2010 Sep 2; 116(9):1506-14.
    View in: PubMed
  69. Richardson P, Laubach J, Mahindra A, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Raje N, Munshi N, Anderson K. The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis. 2010; 2(2):e2010009.
    View in: PubMed
  70. Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, Pai C, Amin S, Tai YT, Richardson PG, Ghobrial IM, Treon SP, Daley JF, Anderson KC, Kutok JL, Munshi NC. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010 Jul 1; 115(26):5385-92.
    View in: PubMed
  71. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 5; 116(5):679-86.
    View in: PubMed
  72. Richardson PG, Laubach J, Mitsiades C, Schlossman RL, Doss D, Colson K, McKenney ML, Noonan K, Warren DL, Ghobrial IM, Munshi NC, Anderson K. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park). 2010 Mar; 24(3 Suppl 2):22-9.
    View in: PubMed
  73. Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1422-8.
    View in: PubMed
  74. Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, Chuma S, Harris B, Leduc R, Rourke M, Ansell SM, Deangelo D, Dispenzieri A, Bergsagel L, Reeder C, Anderson KC, Richardson PG, Treon SP, Witzig TE. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1408-14.
    View in: PubMed
  75. Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.
    View in: PubMed
  76. Roccaro AM, Sacco A, Aujay M, Ngo HT, Azab AK, Azab F, Quang P, Maiso P, Runnels J, Anderson KC, Demo S, Ghobrial IM. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood. 2010 May 20; 115(20):4051-60.
    View in: PubMed
  77. Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res. 2010 Feb 1; 16(3):1033-41.
    View in: PubMed
  78. Roccaro AM, Sacco A, Husu EN, Pitsillides C, Vesole S, Azab AK, Azab F, Melhem M, Ngo HT, Quang P, Maiso P, Runnels J, Liang MC, Wong KK, Lin C, Ghobrial IM. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood. 2010 Jan 21; 115(3):559-69.
    View in: PubMed
  79. Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG. Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):947-60.
    View in: PubMed
  80. Stedman J, Roccaro A, Ghobrial IM. Individualizing treatment for Waldenstrom's macroglobulinemia. Expert Rev Hematol. 2009 Oct; 2(5):473-6.
    View in: PubMed
  81. Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial IM, Doss D, Warren DL, Lunde LE, McKenney M, Delaney C, Mitsiades CS, Hideshima T, Dalton W, Knight R, Esseltine DL, Anderson KC. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009 Dec 1; 27(34):5713-9.
    View in: PubMed
  82. Ngo HT, Azab AK, Farag M, Jia X, Melhem MM, Runnels J, Roccaro AM, Azab F, Sacco A, Leleu X, Anderson KC, Ghobrial IM. Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia. Clin Cancer Res. 2009 Oct 1; 15(19):6035-41.
    View in: PubMed
  83. Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, Carreau N, Hideshima T, Anderson KC, Richardson PG. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia. 2009 Dec; 23(12):2222-32.
    View in: PubMed
  84. Laubach JP, Mitsiades CS, Hideshima T, Schlossman R, Chauhan D, Munshi N, Ghobrial I, Carreau N, Anderson KC, Richardson PG. Bortezomib in the management of multiple myeloma. Cancer Manag Res. 2009; 1:107-17.
    View in: PubMed
  85. Venon MD, Roccaro AM, Gay J, Moreau AS, Dulery R, Facon T, Ghobrial IM, Leleu X. Front line treatment of elderly multiple myeloma in the era of novel agents. Biologics. 2009; 3:99-109.
    View in: PubMed
  86. Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, Willen M, Matous J, Mattern J, Diener JG, Keogh GP, Myers TJ, Boral A, Birner A, Esseltine DL, Ghobrial IM. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009 Aug 10; 27(23):3830-5.
    View in: PubMed
  87. Azab AK, Azab F, Blotta S, Pitsillides CM, Thompson B, Runnels JM, Roccaro AM, Ngo HT, Melhem MR, Sacco A, Jia X, Anderson KC, Lin CP, Rollins BJ, Ghobrial IM. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood. 2009 Jul 16; 114(3):619-29.
    View in: PubMed
  88. Laubach JP, Mitsiades CS, Roccaro AM, Ghobrial IM, Anderson KC, Richardson PG. Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia. Leuk Lymphoma. 2009 May; 50(5):694-702.
    View in: PubMed
  89. Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem MR, Lin CP, Ribatti D, Rollins BJ, Witzig TE, Anderson KC, Ghobrial IM. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009 Jun 25; 113(26):6669-80.
    View in: PubMed
  90. Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R, Schop RF, Price-Troska T, Henderson K, Sacco A, Azab F, Greipp P, Gertz M, Hayman S, Rajkumar SV, Carpten J, Chesi M, Barrett M, Stewart AK, Dogan A, Bergsagel PL, Ghobrial IM, Fonseca R. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res. 2009 Apr 15; 69(8):3579-88.
    View in: PubMed
  91. Pascal L, Gay J, Willekens C, Wemeau M, Balkaran S, Robu D, Roccaro A, Morel P, Ghobrial I, Leleu X. Bortezomib and Waldenstrom's macroglobulinemia. Expert Opin Pharmacother. 2009 Apr; 10(5):909-16.
    View in: PubMed
  92. Leleu X, Tamburini J, Roccaro A, Morel P, Soumerai J, Lévy V, Wemeau M, Balkaran S, Poulain S, Hunter ZR, Ghobrial IM, Treon SP, Leblond V. Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy. Clin Lymphoma Myeloma. 2009 Mar; 9(1):71-3.
    View in: PubMed
  93. Braggio E, Keats JJ, Leleu X, Wier SV, Jimenez-Zepeda VH, Schop RF, Chesi M, Barrett M, Stewart AK, Dogan A, Bergsagel PL, Ghobrial IM, Fonseca R. High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas. Clin Lymphoma Myeloma. 2009 Mar; 9(1):39-42.
    View in: PubMed
  94. Roccaro AM, Sacco A, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem M, Moreau AS, Ghobrial IM. Role of proteasome inhibition in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar; 9(1):94-6.
    View in: PubMed
  95. Ghobrial IM, Leleu X, Azab AK, Runnels J, Jia X, Ngo H, Melhem M, Azab F, Sacco A, Quang P, Burwick N, Moreau AS, Husu E, Farag M, Roccaro A. Novel therapeutic agents in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar; 9(1):84-6.
    View in: PubMed
  96. Leleu X, Hunter ZR, Xu L, Roccaro AM, Moreau AS, Santos DD, Hatjiharissi E, Bakthavachalam V, Adamia S, Ho AW, Soumerai J, Patterson CJ, Manning RJ, Hamilton S, Verselis S, Fox E, Carrasco R, Ghobrial IM, Treon SP. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. Br J Haematol. 2009 Apr; 145(1):59-63.
    View in: PubMed
  97. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, Alt C, Burwick N, Roccaro AM, Ngo HT, Farag M, Melhem MR, Sacco A, Munshi NC, Hideshima T, Rollins BJ, Anderson KC, Kung AL, Lin CP, Ghobrial IM. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009 Apr 30; 113(18):4341-51.
    View in: PubMed
  98. Ghobrial IM, Laubach JP, Soiffer RJ. Finding the right academic job. Hematology Am Soc Hematol Educ Program. 2009; 729-33.
    View in: PubMed
  99. Leleu X, Gay J, Roccaro AM, Moreau AS, Poulain S, Dulery R, Champs BB, Robu D, Ghobrial IM. Update on therapeutic options in Waldenström macroglobulinemia. Eur J Haematol. 2009 Jan; 82(1):1-12.
    View in: PubMed
  100. Ghobrial IM, Stewart AK. ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma? Hematology Am Soc Hematol Educ Program. 2009; 587-9.
    View in: PubMed
  101. Gertz MA, Ghobrial I, Luc-Harousseau J. Multiple myeloma: biology, standard therapy, and transplant therapy. Biol Blood Marrow Transplant. 2009 Jan; 15(1 Suppl):46-52.
    View in: PubMed
  102. Roccaro AM, Sacco A, Chen C, Runnels J, Leleu X, Azab F, Azab AK, Jia X, Ngo HT, Melhem MR, Burwick N, Varticovski L, Novina CD, Rollins BJ, Anderson KC, Ghobrial IM. microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. Blood. 2009 Apr 30; 113(18):4391-402.
    View in: PubMed
  103. Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, Ciccarelli BT, Sacco A, Ioakimidis L, Adamia S, Moreau AS, Patterson CJ, Ghobrial IM, Treon SP. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009 Jan 10; 27(2):250-5.
    View in: PubMed
  104. Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V, Fermand JP, Merlini G, Morel P, Morra E, Ocio EM, Owen R, Ghobrial IM, Seymour J, Kyle RA, Treon SP. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009 Jan 1; 27(1):120-6.
    View in: PubMed
  105. Leleu X, Xu L, Jia X, Sacco A, Farag M, Hunter ZR, Moreau AS, Ngo HT, Hatjiharissi E, Ho AW, Santos DD, Adamia S, O'Connor K, Ciccarelli B, Soumerai J, Manning RJ, Patterson CJ, Roccaro AM, Ghobrial IM, Treon SP. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood. 2009 Jan 15; 113(3):626-34.
    View in: PubMed
  106. Roccaro AM, Ghobrial IM, Blotta S, Treon SP, Malagola M, Anderson KC, Richardson PG, Russo D. Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics. 2008 Sep; 2(3):419-31.
    View in: PubMed
  107. Oton AB, Wang H, Leleu X, Melhem MF, George D, Lacasce A, Foon K, Ghobrial IM. Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk Lymphoma. 2008 Sep; 49(9):1738-44.
    View in: PubMed
  108. Richardson PG, San-Miguel J, Lonial S, Reece D, Jakubowiak A, Hussein M, Jagannath S, Mitsiades CS, Raje N, Kaufman J, Avigan D, Ghobrial I, Schlossman RL, Munshi N, Dalton W, Anderson KC. The research mission in myeloma. Leukemia. 2009 Feb; 23(2):422-3; author reply 423-4.
    View in: PubMed
  109. Ansell SM, Inwards DJ, Rowland KM, Flynn PJ, Morton RF, Moore DF, Kaufmann SH, Ghobrial I, Kurtin PJ, Maurer M, Allmer C, Witzig TE. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer. 2008 Aug 1; 113(3):508-14.
    View in: PubMed
  110. Alsayed Y, Leleu X, Leontovich A, Oton AB, Melhem M, George D, Ghobrial IM. Proteomics analysis in post-transplant lymphoproliferative disorders. Eur J Haematol. 2008 Oct; 81(4):298-303.
    View in: PubMed
  111. Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther. 2008 Jul; 8(7):1053-72.
    View in: PubMed
  112. Leleu X, Roccaro AM, Moreau AS, Dupire S, Robu D, Gay J, Hatjiharissi E, Burwik N, Ghobrial IM. Waldenstrom macroglobulinemia. Cancer Lett. 2008 Oct 18; 270(1):95-107.
    View in: PubMed
  113. Moreau AS, Jia X, Patterson CJ, Roccaro AM, Xu L, Sacco A, O'Connor K, Soumerai J, Ngo HT, Hatjiharissi E, Hunter ZR, Ciccarelli B, Manning R, Ghobrial IM, Leleu X, Treon SP. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. Br J Haematol. 2008 Sep; 142(5):775-85.
    View in: PubMed
  114. Leleu X, Moreau AS, Weller E, Roccaro AM, Coiteux V, Manning R, Nelson M, Leduc R, Robu D, Dupire S, Hatjiharissi E, Burwick N, Darre S, Hennache B, Treon SP, Facon T, Gertz MA, Ghobrial IM. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2008 Jun; 49(6):1104-7.
    View in: PubMed
  115. Burwick N, Roccaro AM, Leleu X, Ghobrial IM. Targeted therapies in Waldenström macroglobulinemia. Curr Opin Investig Drugs. 2008 Jun; 9(6):631-7.
    View in: PubMed
  116. Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J, Moreau AS, Burwick N, Azab AK, Roccaro A, Azab F, Sacco A, Farag M, Sackstein R, Ghobrial IM. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood. 2008 Jul 1; 112(1):150-8.
    View in: PubMed
  117. Roccaro AM, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, Xu L, Ciccarelli B, Patterson CJ, Ngo HT, Russo D, Vacca A, Dammacco F, Anderson KC, Ghobrial IM, Treon SP. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Clin Cancer Res. 2008 Mar 15; 14(6):1849-58.
    View in: PubMed
  118. Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M, Sacco A, Ngo HT, Runnels J, Melhem MR, Burwick N, Azab A, Azab F, Hunter Z, Hatjiharissi E, Carrasco DR, Treon SP, Witzig TE, Hideshima T, Brown M, Anderson KC, Ghobrial IM. Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood. 2008 May 15; 111(10):5068-77.
    View in: PubMed
  119. Moreau AS, Sebti Y, Duhamel A, Roccaro AM, Coiteux V, Gastinne T, Le Friec G, Burwick N, Amiot L, Ho AW, Poulain S, Hennache B, Hunter ZR, Dessaint JP, Ghobrial IM, Treon SP, Facon T, Zorn E, Leleu X. Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia. Eur J Haematol. 2008 Jun; 80(6):503-9.
    View in: PubMed
  120. Roccaro AM, Leleu X, Sacco A, Jia X, Melhem M, Moreau AS, Ngo HT, Runnels J, Azab A, Azab F, Burwick N, Farag M, Treon SP, Palladino MA, Hideshima T, Chauhan D, Anderson KC, Ghobrial IM. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2008 May 1; 111(9):4752-63.
    View in: PubMed
  121. Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, Roccaro A, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hideshima T, Roodman DG, Anderson KC, Ghobrial IM. Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin Cancer Res. 2008 Feb 1; 14(3):865-74.
    View in: PubMed
  122. Leleu X, Jia X, Runnels J, Ngo HT, Moreau AS, Farag M, Spencer JA, Pitsillides CM, Hatjiharissi E, Roccaro A, O'Sullivan G, McMillin DW, Moreno D, Kiziltepe T, Carrasco R, Treon SP, Hideshima T, Anderson KC, Lin CP, Ghobrial IM. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2007 Dec 15; 110(13):4417-26.
    View in: PubMed
  123. Treon SP, Hatjiharissi E, Leleu X, Moreau AS, Roccaro A, Hunter ZR, Soumerai JD, Ciccarelli B, Xu L, Sacco A, Ngo HT, Jia X, Yang C, Adamia S, Branagan AR, Ho AW, Santos DD, Tournilhac O, Manning RJ, Leduc R, O'Connor K, Nelson M, Patterson CJ, Ghobrial I. Novel agents in the treatment of Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2007 Aug; 7 Suppl 5:S199-206.
    View in: PubMed
  124. Younes H, Leleu X, Hatjiharissi E, Moreau AS, Hideshima T, Richardson P, Anderson KC, Ghobrial IM. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res. 2007 Jul 1; 13(13):3771-5.
    View in: PubMed
  125. Ghobrial J, Ghobrial IM, Mitsiades C, Leleu X, Hatjiharissi E, Moreau AS, Roccaro A, Schlossman R, Hideshima T, Anderson KC, Richardson P. Novel therapeutic avenues in myeloma: changing the treatment paradigm. Oncology (Williston Park). 2007 Jun; 21(7):785-92; discussion 798-800.
    View in: PubMed
  126. Ghobrial IM, Ghobrial J, Leleu X, Hatjiharissi E, Mitsiades C, Richardson P, . Novel Therapeutic Avenues in Myeloma: Changing the Paradigm. Oncology. 2007.
  127. Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood. 2007 Sep 1; 110(5):1656-63.
    View in: PubMed
  128. Hatjiharissi E, Ngo H, Leontovich AA, Leleu X, Timm M, Melhem M, George D, Lu G, Ghobrial J, Alsayed Y, Zeismer S, Cabanela M, Nehme A, Jia X, Moreau AS, Treon SP, Fonseca R, Gertz MA, Anderson KC, Witzig TE, Ghobrial IM. Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res. 2007 Apr 15; 67(8):3777-84.
    View in: PubMed
  129. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, Spencer JA, Kimlinger T, Ghobrial JM, Jia X, Lu G, Timm M, Kumar A, Côté D, Veilleux I, Hedin KE, Roodman GD, Witzig TE, Kung AL, Hideshima T, Anderson KC, Lin CP, Ghobrial IM. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007 Apr 1; 109(7):2708-17.
    View in: PubMed
  130. Ghobrial IM, Leleu X, Hatjiharissi E, Hideshima T, Mitsiades C, Schlossman R, Anderson KC, Richardson P. Emerging drugs in multiple myeloma. Expert Opin Emerg Drugs. 2007 Mar; 12(1):155-63.
    View in: PubMed
  131. Moreau AS, Jia X, Ngo HT, Leleu X, O'Sullivan G, Alsayed Y, Leontovich A, Podar K, Kutok J, Daley J, Lazo-Kallanian S, Hatjiharissi E, Raab MS, Xu L, Treon SP, Hideshima T, Anderson KC, Ghobrial IM. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood. 2007 Jun 1; 109(11):4964-72.
    View in: PubMed
  132. Burwick N, Leleu X, Ghobrial IM, Mitsiades C, Richardson P. Novel treatments in multiple myeloma. Hospital Pharmacy Europe. 2007; 81-83.
  133. Leleu X, Jia X, Moreau AS, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. Perifosine, an oral bioactive AKT inhibitor induces in vitro and in vivo antitumor activity in Waldenstrom Macroglobulinemia. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.
  134. Leleu X, Moreau AS, Jia X, O'Sullivan, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. The Proteasome inhibitor NPI-0052 incombination with bortezomib induces antitumor activity in Waldenstrom Macroglobulinemia. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.
  135. O'Sullivan, Leleu X, Moreau AS, Jia X, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. The combination of the mTOR inhibitor rapamycin and proteasome inhibitor Bortezomib is synergistic in vitro in Multiple Myeloma. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.
  136. Runnels J, Pitsillides C, Spenser J, Ngo N, Hatjiharissi E, Leleu X, Moreau AS, Jia X, Hideshima T, Anderson KC, Ghobrial IM. A novel real-time in vivo homing model of multiple myeloma. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.
  137. Moreau AS, Jia X, O'Sullivan, Leleu X, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. A selective protein kinase C inhibitor Enzastaurin, induces in vitro and in vivo cytotoxicity in Waldenstrom Macroglobulinemia. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.
  138. Ghobrial IM, Dimopoulos A. Update on novel therapeutic agents in Waldenstom Macroglobulinemia. Translational Therapeutic Strategies in Multiple Myeloma. 2007.
  139. Leleu X, Moreau AS, Jia X, O'Sullivan, Ngo N Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. The PI3k/Akt pathway is an important regulator of homing and adhesion in Waldenstrom Macroglobulinemia. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.
  140. Leleu X, Moreau AS, Jia X, O'Sullivan, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. Novel Agent Perifosine enhances antitumor activity of Bortezomib and rituximab in Waldenstrom Macroglobulinemia. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.
  141. Leleu X, O'Connor K, Ho AW, Santos DD, Manning R, Xu L, Hatjiharissi E, Moreau AS, Branagan AR, Hunter ZR, Dimmock EA, Soumerai J, Patterson C, Ghobrial I, Treon SP. Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. Am J Hematol. 2007 Jan; 82(1):83-4.
    View in: PubMed
  142. Ghobrial IM, Foon, K. Non-Hodgkin Lymphoma. William's Hematology. 2007.
  143. Ngo N, Hatjiharissi E, Leleu X, Runnels J, Moreau AS, Jia X, O'Sullivan, Treon S, Hideshima T, Anderson KC, Ghobrial IM. The CXCR4/SDF-1 axis regulates migration and adhesion in Waldenstrom macroglobulinemia. XIth Internatinal Workshop on Multiple Myeloma & IVth International Workshop on Waldenstrom's Macroglobulinemia. 2007.
  144. Huston A, Leleu X, Jia X, Moreau A, Ngo H, Runnels J, Anderson J, Alsayed Y, Richardson P, Hideshima T, Roodman D, Anderson KC, Ghobrial IM. Targeting Akt and HSP90 produces synergistic Multiple Myeloma cell cytoxicity in the bone marrow microenvironment. Blood. 2007.
  145. Richardson P, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Chauhan D, Munshi N, Anderson K. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007; 317-23.
    View in: PubMed
  146. Younes H, Leleu X, Hatjiharissi E, Moreau AS, Anderson KC, Ghobrial IM. Targeting the PI3K pathway in Multiple Myeloma. Clinical Cancer Research. 2007.
  147. Hwang JJ, Ghobrial IM, Anderson KC. New frontiers in the treatment of multiple myeloma. ScientificWorldJournal. 2006; 6:1475-503.
    View in: PubMed
  148. Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res. 2006 Nov 15; 12(22):6826-35.
    View in: PubMed
  149. Richardson PG, Mitsiades C, Ghobrial I, Anderson K. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol. 2006 Nov; 18(6):598-608.
    View in: PubMed
  150. Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, Schlossman R, Ghobrial I, Raje N, Munshi N, Anderson KC. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 2007 Apr 5; 26(16):2374-80.
    View in: PubMed
  151. Aggarwal R, Ghobrial IM, Roodman GD. Chemokines in multiple myeloma. Exp Hematol. 2006 Oct; 34(10):1289-95.
    View in: PubMed
  152. Ghobrial IM, Richardson P. The emerging role of novel therpeutic agents int he management of patients with multiple myeloma. Community Oncology. 2006; 3(9):575-582.
  153. Schop RF, Van Wier SA, Xu R, Ghobrial I, Ahmann GJ, Greipp PR, Kyle RA, Dispenzieri A, Lacy MQ, Rajkumar SV, Gertz MA, Fonseca R. 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet. 2006 Sep; 169(2):150-3.
    View in: PubMed
  154. Chng WJ, Schop RF, Price-Troska T, Ghobrial I, Kay N, Jelinek DF, Gertz MA, Dispenzieri A, Lacy M, Kyle RA, Greipp PR, Tschumper RC, Fonseca R, Bergsagel PL. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 2006 Oct 15; 108(8):2755-63.
    View in: PubMed
  155. Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM, Wolf RC, Hoffmann RJ, Lust JA, Witzig TE, Lacy MQ, Dispenzieri A, Vincent Rajkumar S, Zeldenrust SR, Greipp PR, Kyle RA. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2006 Apr; 133(2):158-64.
    View in: PubMed
  156. Runnels J, Pitsillides C, Spenser J, NGO N, Hatjiharissi E, Leleu X, Moreau AS, Jia X, Hideshima T, Anderson KC, Ghobrial IM. A novel real-time in vivo homing model of multiple myeloma. ASH. 2006.
  157. Leleu X, Jia X, Moreau AS, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. Perifosine, an oral bioactive AKT inhibitor induces in vitro and in vivo antitumor activity in Waldenstroms Macroglobulinemia. ASH. 2006.
  158. O'Sullivan, Leleu X, Moreau AS, Jia X, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. The combination of the mTOR inhibitor rapamycin and proteasome inhibitor Bortezomib in synergistic in vitro in Multiple Myeloma. ASH. 2006.
  159. Ngo N, Hatjiharissi E, Leleu X, Runnels J, Moreau AS, Jia X, O'Sullivan, Treon S, Hideshima T, Anderson KC, Ghobrial IM. The CXCR4/SDF-1 axis regulates migration and adhesion in Waldenstrom Macroglobulinemia. ASH. 2006.
  160. Leleu X, Moreau AS, Jia X, O'Sullivan, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. Novel Agent Perifosine enhances antitumor activity of Bortezomib and rituximab in Waldenstrom Macroglobulinemia. ASH. 2006.
  161. Leleu X, Moreau AS, Jia X, O'Sullivan, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC< Ghobrial IM. The Proteasome inhibitor NPI-0052 incombination with bortezomib induces antitumor activity in Waldenstrom Macroglobulinemia. ASH. 2006.
  162. Moreau AS, Jia X, O'Sullivan, Leleu X, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM. A selection protein kinase C inhibitor Enzastaurin, induces in vitro and in vivo cytotoxicity in Waldenstrom Macroglobulinemia. ASH. 2006.
  163. Leleu X, Moreau AS, Jia X, O'Sullivan, Ngo N, Hatjiharissi E, Runnels J, Treon S, Hideshima T, Anderson KC, Ghobrial IM . The PI3K/Akt pathway is an important regulator of homing and adhesion in Waldenstrom Macroglobulinemia. ASH. 2006.
  164. Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, Donnenberg A, Ghobrial I, Mapara MY, Stirling D, Roodman D, Lentzsch S. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood. 2006 Apr 15; 107(8):3098-105.
    View in: PubMed
  165. Ghobrial IM, Habermann TM, Maurer MJ, Geyer SM, Ristow KM, Larson TS, Walker RC, Ansell SM, Macon WR, Gores GG, Stegall MD, McGregor CG. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol. 2005 Oct 20; 23(30):7574-82.
    View in: PubMed
  166. Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF, Dakhil SR, Gross H, Kaufmann SH. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005 Aug 10; 23(23):5347-56.
    View in: PubMed
  167. Ehrlich LA, Chung HY, Ghobrial I, Choi SJ, Morandi F, Colla S, Rizzoli V, Roodman GD, Giuliani N. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood. 2005 Aug 15; 106(4):1407-14.
    View in: PubMed
  168. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005 May-Jun; 55(3):178-94.
    View in: PubMed
  169. Ghobrial IM, Weenig RH, Pittlekow MR, Qu G, Kurtin PJ, Ristow K, Ansell SM. Clinical outcome of patients with subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma. 2005 May; 46(5):703-8.
    View in: PubMed
  170. Eckel-Passow JE, Hoering A, Therneau TM, Ghobrial I. Experimental design and analysis of antibody microarrays: applying methods from cDNA arrays. Cancer Res. 2005 Apr 15; 65(8):2985-9.
    View in: PubMed
  171. Ghobrial IM, Habermann TM, Ristow KM, Ansell SM, Macon W, Geyer SM, McGregor CG. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma. 2005 Feb; 46(2):191-6.
    View in: PubMed
  172. Ghobrial IM, Habermann TM, Macon WR, Ristow KM, Larson TS, Walker RC, Ansell SM, Gores GJ, Stegall MD, McGregor CG. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation. 2005 Jan 27; 79(2):244-7.
    View in: PubMed
  173. Ghobrial IM, McCormick DJ, Kaufmann SH, Leontovich AA, Loegering DA, Dai NT, Krajnik KL, Stenson MJ, Melhem MF, Novak AJ, Ansell SM, Witzig TE. Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood. 2005 May 1; 105(9):3722-30.
    View in: PubMed
  174. Alsayed YM, Leontovish A, Timm M, Melhem M, Ghobrial IM. Proteomic analysis of post transplant lymphoproliferative disorders (PTLD) using nanoscale protein microarray techniques. ASH. 2005.
  175. Ghobrial IM, Timm M, Witzig T Hedin K . The Role of CXCR4 Inhibitors as Novel Antiangiogenesis Agents in Cancer Therapy. 10Th International Myeloma Workshop. 2005.
  176. Lu Y, Keller E, Dai J, Escara-Wilke J, Ghobrial IM, et al. Role of cathepsin K in prostate cancer skeletal meastasis. AACR. 2005.
  177. Alsayed YM, Leontocich A, Timm M, Melham M, Ghobrial IM. Proteomic analysis of Waldenstrom Macroglobulinemia (WM) using nanoscale protein microarray techniques. ASH. 2005.
  178. Lanie K, Ganwei L, Ujjal S, Lentsch S, Roodman GD, Ghobrial IM, . Combination of the mTOR inhibitor Rapamycin and HSP90 inhibitor 17AAG in Multiple Myeloma. ASCO. 2005.
  179. Ghobrial IM, Alsayed YM, Timm M, et al. Molecular mechanisms regulating migration and adhesion in response to the chemokine SDF-1 in multiple myeloma (MM). ASH. 2005.
  180. Ghobrial IM, Sigha U, Alsayed YM, et al. Role of the chemokine receptor CXCR4 in Waldenstrom Macroglobulinemia. ASH. 2005.
  181. Ghobrial IM, Timm M, Witzig T . Proteomic Analysis of Targeted Therapeutic Agents in Multiple Myeloma (MM). 10th International Myeloma Workshop. 2005.
  182. Huston A, Singha U, Alsayed YM, Roodman GD, Ghobrial IM. The role of the AKT inhibitor perifosine in migration and adhesion in multiple myeloma (MM). ASH. 2005.
  183. Ghobrial IM, Melhem M, Ujjal S, et al. Role of the CXCR4 inhibitor AMD3100 in mulitple myeloma (MM). ASH. 2005.
  184. Lu Y, Keller E, Yao Z, Taichman R, Ghobrial IM, et al . Zoledronic acid inhibits CXCR-4-mediated prostate cancer cell invasion through an NFɻB independent pathway in vitro. AACR. 2005.
  185. Ghobrial IM, Timm M, Witzig T . Proteomic Analysis of Multiple Myeloma Identifies Potential Targets for Drug Therapy. 10Th International Myeloma Workshop. 2005.
  186. Ghobrial IM, Ghobrial JM, Bramati P, Kumar A, Hedin K, Witzig T. Molecular Mechanisms Involved in Homing and Migration of Plasma Cells in Response to CXCR4 Stimulation and Downstream Activation of The PI3K Pathway. 10Th International Myeloma Workshop. 2005.
  187. Huston A, Leontocich A, Timm M, Alsayed YM, Ghobrial IM. Proteomic analysis identifies differences in multiple myeloma (MM) cells sensitive and resistant to AKT inhibition. ASH. 2005.
  188. Francis L, Anderson J, Timm M, Roodman GD, Ghobrial IM. The effect of rapamycin, 17-AAG and the combination on the bone marrow microenvironment in Multiple Myeloma (MM). ASH. 2005.
  189. Alsayed YM, Singha U, Francis L, Roodman GD, Ghobrial IM. Combination of the mTOR inhibitor rapamycin with the HSP90 inhibitor 17-AAG has synergistic activity in EBV positive and negative post transplant lymphoproliferative disorders (PTLD). ASH. 2005.
  190. Lu Y, Keller E, Yao Z, Taichman R, Ghobrial IM, et al. Zoledronic acid inhibits CXCR-4 mediated prostate cancer cell invasion through an NFE>>B independent pathway in vitro. AACR. 2005.
  191. Huston A, Alsayed YM, Singha U, Francis L, Roodman GD, Ghobrial IM. Combination of the AKT inhibitor perifosine with the HSP90 inhibitor 17-(dimethylaminoethyulamino)-17-demethoxygeldanamycin (17-DMAG) has synergistic activity in Multiple Myeloma (MM). ASH. 2005.
  192. Lu Y, Keller E, Dai J, Escara-Wilke J, Ghobrial IM, et al . Role of cathepsin K in prostate cancer skeletal metastasis. AACR. 2005.
  193. Ghobrial IM, Timm M, Witzig T. Proteomic Analysis of Multiple Myeloma Identifies Potential Targets for Drug Therapy. 10th Annual Myeloma Workshop. 2005.
  194. Alsayed YM, Singha U, Huston A, Roodman GD, Ghobrial IM. Differential response to proteosome inhibition in EBV positive and negative lymphoma cell lines: clinical implications in post transplant lymphoproliferative disorders (PtLD). 2005.
  195. Ghobrial IM, Timm M, Witzig T, Kedin K. The Role of CXCR4 inhibitors as Novel Antiangiogenesis Agents in Cancer Therapy. 10th Annyal Internation Myeloma Workshop. 2005.
  196. Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH, Gertz MA. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004 Dec 1; 101(11):2593-8.
    View in: PubMed
  197. Ghobrial IM, Uslan DZ, Call TG, Witzig TE, Gertz MA. Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenström macroglobulinemia does not indicate failure of response. Am J Hematol. 2004 Dec; 77(4):329-30.
    View in: PubMed
  198. Ghobrial IM, Witzig TE. Waldenström macroglobulinemia. Curr Treat Options Oncol. 2004 Jun; 5(3):239-47.
    View in: PubMed
  199. Ghobrial IM, Buadi F, Spinner RJ, Colgan JP, Wolanskyj AP, Dyck PJ, Witzig TE, Micallef IN, O'Neill BP. High-dose intravenous methotrexate followed by autologous stem cell transplantation as a potentially effective therapy for neurolymphomatosis. Cancer. 2004 Jun 1; 100(11):2403-7.
    View in: PubMed
  200. Ghobrial I, Witzig T. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma. Oncology (Williston Park). 2004 May; 18(5):623-30; discussion 633-4, 637-8, 640.
    View in: PubMed
  201. Ghobrial IM, Bunch TJ, Caplice NM, Edwards WD, Miller DV, Litzow MR. Fatal coronary artery disease after unrelated donor bone marrow transplantation. Mayo Clin Proc. 2004 Mar; 79(3):403-6.
    View in: PubMed
  202. Ghobrial IM, Bone ND, Stenson MJ, Novak A, Hedin KE, Kay NE, Ansell SM. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. Mayo Clin Proc. 2004 Mar; 79(3):318-25.
    View in: PubMed
  203. Ghobrial IM, Wolf RC, Pereira DL, Fonseca R, White WL, Colgan JP, Habermann TM, Inwards DJ, Markovic SN, Ansell SM, Micallef IN, Porrata LF, Witzig TE. Therapeutic options in patients with lymphoma and severe liver dysfunction. Mayo Clin Proc. 2004 Feb; 79(2):169-75.
    View in: PubMed
  204. Ghobrial IM, McCormick D, Witzig T . Proteomic analysis of patients with mantle cell lymphoma identifies Hsp90 and other proteins as potential target(s) for drug therapy. ASCO. 2004.
  205. Ghobrial IM, McCormick, Witzig, T . Proteomic analysis of mantle cell lymphoma. National Institute of Health. 2004.
  206. Ghobrial IM, Bone ND, Stenson MJ, Novak A, Hedin KE, Kay NE, Ansell SM . Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. National Institute of Health. 2004.
  207. Ghobrial IM, Timm M, Witzig T . Proteomic Analysis of Targeted Therapeutic Agents in Multiple Myeloma (MM). ASH. 2004.
  208. Ghobrial IM, Timm M, Greipp P, Fonseca R, Witzig T . Proteomic Analysis of Multiple Myeloma Identifies Potential Targets for Drug Therapy . ASH. 2004.
  209. Ghobrial IM, Ghobrial JM, Bramati P, Kumar A, Hedin K, Witzig T . Molecular Mechanisms Involved in Homing and Migration of Plasma Cells in Response to CXCR4 Stimulation and Downstream Activation of The PI3K Pathway. ASH. 2004.
  210. Ghobrial IM. Kaufman S, Witzig T . CCI-779 inhibits phosphorylation of ribosomal S6 (pS6) in mantle cell lymphoma. AACR. 2004.
  211. Chung T, Kim S, Baker A, Price-Troska T, Xu R, Ghobrial IM, Greipp R, Rajkumar SV, Gertz MA, Van Weir S, Ahmann G, Carpten J, Fonseca R . Characterization of Waldenström Macroglobulinemia Subtypes Using Global Gene Expression Profiling. ASH. 2004.
  212. Riter HG, Ghobrial IM. Renal cell carcinoma with acrometastasis and scalp metastasis. Mayo Clin Proc. 2004 Jan; 79(1):76.
    View in: PubMed
  213. Eckel JE, Hoering A, Ghobrial IM . Experimental Design & Analysis of Protein Array Data: Applying Methods from cDNA Arrays. ASH. 2004.
  214. Ghobrial IM, Ghobrial JM, Bramati P, Kumar A, Hedin K, Witzig T . Molecular Mechanisms Involved in Homing and Migration of B-Chronic Lymphocytic Leukemia (CLL) in Response to CXCR4 Stimulation and Downstream Activation of the PI3K Pathway. ASH. 2004.
  215. Witzig TE, Geyer S, Ghobrial IM, et al . Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. ASH . 2004.
  216. Ghobrial IM, Timm M, Greipp P, Witzig T. Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS) Identifies Potential Targets for Drug Therapy. ASH. 2004.
  217. Ghobrial IM, Timm M, Witzig T, Hedin K . The Role of CXCR4 Inhibitors as Novel Antiangiogenesis Agents in Cancer Therapy. ASH. 2004.
  218. Ghobrial IM, Otteman LA, White WL. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. N Engl J Med. 2003 Dec 25; 349(26):2570-2; discussion 2570-2.
    View in: PubMed
  219. Ghobrial IM, Gertz MA, Fonseca R. Waldenström macroglobulinaemia. Lancet Oncol. 2003 Nov; 4(11):679-85.
    View in: PubMed
  220. Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol. 2003 Sep-Oct; 1(3):194-205.
    View in: PubMed
  221. Ghobrial IM, Dispenzieri A, Bundy KL, Gastineau DA, Rajkumar SV, Therneau TM, Lacy MQ, Witzig TE, Litzow MR, Christensen BR, Hayman S, Pribula CG, Gertz MA. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant. 2003 Sep; 32(6):587-92.
    View in: PubMed
  222. Ghobrial IM, Habermann TM, Geyer S, Ansell S. Rituximab and IPI are prognostic indicators in post transplant lymphoproliferative disorders (PTLD). American Society of Clinical Oncology. 2003.
  223. Ghobrial IM, Ansell AM . Subcutaneous Panniculitis-like T cell lymphoma: clinical presentation and follow up of 17 patients. Blood. 2003.
  224. Xu R, Van Wier S, Ghobrial IM, Schop R, Ahmann G, Greipp P, Kyle R, Rajkumar SV, Gertz MA, Fonseca R . Deletions of 6q predominantly involve band q23 and distinguish Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Blood. 2003.
  225. Ghobrial IM, Wolf R, Fonseca R, Witzig T. . Therapeutic options in patients with lymphoma and severe liver dysfunction. Blood. 2003.
  226. Ghobrial IM, Habermann T . Differences between early and late Post Transplant Lymphoproliferative Disorders: are they two different diseases. Blood. 2003.
  227. Gthobrial IM, Fonseca R, Gertz M, Greipp P, Kyle R. Prognostic model for 506 patients diagnosed with Waldenstrom Macroglobulinemia,. Blood. 2003.
  228. Ghobrial IM, Habermann T . Prognostic model for patients with Post Transplant Lymphoproliferative Disorders. Blood. 2003.
  229. Ghobrial IM, Fonseca R, Gertz M, Greipp P, Kyle R. . The IgM flare in patients diagnosed with Waldenstrom Macroglobulinemia and treated with rituximab: an ECOG study. Blood. 2003.
  230. Ghobrial IM, ONeill B . CNS Post Transplant Lymphoproliferative Disorders: therapy with rituximab. Blood. 2003.
  231. Ghobrial IM, Bone ND, Stenson MJ, Novak A, Hedin KE, Kay NE, Ansell SM. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Panpacific Lymphoma Conference. 2003.
  232. Ghobrial IM, Adjei AA. Inhibitors of the ras oncogene as therapeutic targets. Hematol Oncol Clin North Am. 2002 Oct; 16(5):1065-88.
    View in: PubMed
  233. Woodle ES, Thistlethwaite JR, Jolliffe LK, Ghobrial I, Fuccello AJ, Stuart FP, Bluestone JA. T-cell activation and lymphokine production induced by antihuman CD3 monoclonal antibodies. Transplant Proc. 1991 Feb; 23(1 Pt 1):81-2.
    View in: PubMed
  234. Wong JT, Eylath AA, Ghobrial I, Colvin RB. The mechanism of anti-CD3 monoclonal antibodies. Mediation of cytolysis by inter-T cell bridging. Transplantation. 1990 Oct; 50(4):683-9.
    View in: PubMed
  235. Raskova J, Ghobrial I, Shea SM, Ebert EC, Eisinger RP, Raska K. T cells in patients undergoing chronic hemodialysis: mitogenic response, suppressor activity, and interleukin-2 production and receptor generation. Diagn Immunol. 1986; 4(4):209-16.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Ghobrial's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_